EX-23.1 3 d897427dex231.htm EX-23.1 EX-23.1

Exhibit 23.1

 

LOGO

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 13, 2025 relating to the financial statements of Enliven Therapeutics, Inc. appearing in the Annual Report on Form 10-K of Enliven Therapeutics, Inc. for the year ended December 31, 2024.

 

/s/ Deloitte & Touche, LLP
San Francisco, California
March 13, 2025